aav9-glb1
Gene therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 5, 2019 (NCT03952637)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Beta-galactosidaseSupplementation
GLB1 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03952637 | Phase 1/Phase 2 (Phase 2) | Jul 5, 2019 | Axovant Sciences Inc, National Human Genome Research Institute (NHGRI) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Axovant Sciences Inc | For profit | 1 | 0 | 1 | 2019 |
| National Human Genome Research Institute (NHGRI) | Government | 1 | 1 | 1 | 2019 |
2 organizations
Page 1 / 1